{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T08:38:22Z","timestamp":1776674302122,"version":"3.51.2"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d\u2019Ajuts Universitaris i de Recerca","doi-asserted-by":"crossref","award":["2021SGR00782"],"award-info":[{"award-number":["2021SGR00782"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"DOI":"10.1186\/s12974-026-03768-5","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:23:28Z","timestamp":1773285808000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bile acid scaffold engineering reveals an androstane-triol derivative as a potent immunomodulator with therapeutic efficacy in EAE"],"prefix":"10.1186","volume":"23","author":[{"given":"Laura","family":"Calvo-Barreiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imane","family":"Boutitah-Benyaich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herena","family":"Eixarch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Espejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moustafa T.","family":"Gabr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"3768_CR1","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41392-025-02415-4","volume":"10","author":"I Boutitah-Benyaich","year":"2025","unstructured":"Boutitah-Benyaich I, Eixarch H, Villacieros-Alvarez J, Hervera A, Cobo-Calvo A, Montalban X, Espejo C. Multiple sclerosis: molecular pathogenesis and therapeutic intervention. Signal Transduct Target Ther. 2025;10:324.","journal-title":"Signal Transduct Target Ther"},{"key":"3768_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","volume":"403","author":"D Jakimovski","year":"2024","unstructured":"Jakimovski D, Bittner S, Zivadinov R, Morrow SA, Benedict RH, Zipp F, Weinstock-Guttman B. Multiple sclerosis. Lancet. 2024;403:183\u2013202.","journal-title":"Lancet"},{"key":"3768_CR3","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502\u201317.","journal-title":"Lancet"},{"key":"3768_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/ng0896-469","volume":"13","author":"JL Haines","year":"1996","unstructured":"Haines JL, Ter-Minassian M, Bazyk A, Gusella JF, Kim DJ, Terwedow H, Pericak-Vance MA, Rimmler JB, Haynes CS, Roses AD, et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet. 1996;13:469\u201371.","journal-title":"Nat Genet"},{"key":"3768_CR5","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/ng.2770","volume":"45","author":"IMSG Consortium","year":"2013","unstructured":"Consortium IMSG. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45:1353\u201360.","journal-title":"Nat Genet"},{"key":"3768_CR6","doi-asserted-by":"publisher","unstructured":"International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019;365(6460):eaav7188. https:\/\/doi.org\/10.1126\/science.aav7188. PMID: 31604244; PMCID: PMC7241648.","DOI":"10.1126\/science.aav7188"},{"key":"3768_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41586-023-06250-x","volume":"619","author":"IMSG Consortium","year":"2023","unstructured":"Consortium IMSG. Locus for severity implicates CNS resilience in progression of multiple sclerosis. Nature. 2023;619:323\u201331.","journal-title":"Nature"},{"key":"3768_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1055\/s-0036-1579693","volume":"36","author":"A Ascherio","year":"2016","unstructured":"Ascherio A, Munger KL. Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention-An Update. Semin Neurol. 2016;36:103\u201314.","journal-title":"Semin Neurol"},{"key":"3768_CR9","doi-asserted-by":"publisher","unstructured":"Alfredsson L, Olsson T. Lifestyle and Environmental Factors in Multiple Sclerosis. Cold Spring Harb Perspect Med. 2019;9(4):a028944. https:\/\/doi.org\/10.1101\/cshperspect.a028944. PMID: 29735578; PMCID: PMC6444694.","DOI":"10.1101\/cshperspect.a028944"},{"key":"3768_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.autrev.2017.11.019","volume":"17","author":"L Calvo-Barreiro","year":"2018","unstructured":"Calvo-Barreiro L, Eixarch H, Montalban X, Espejo C. Combined therapies to treat complex diseases: The role of the gut microbiota in multiple sclerosis. Autoimmun Rev. 2018;17:165\u201374.","journal-title":"Autoimmun Rev"},{"key":"3768_CR11","doi-asserted-by":"publisher","first-page":"e0137429","DOI":"10.1371\/journal.pone.0137429","volume":"10","author":"S Miyake","year":"2015","unstructured":"Miyake S, Kim S, Suda W, Oshima K, Nakamura M, Matsuoka T, Chihara N, Tomita A, Sato W, Kim SW, et al. Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters. PLoS ONE. 2015;10:e0137429.","journal-title":"PLoS ONE"},{"key":"3768_CR12","doi-asserted-by":"publisher","first-page":"28484","DOI":"10.1038\/srep28484","volume":"6","author":"J Chen","year":"2016","unstructured":"Chen J, Chia N, Kalari KR, Yao JZ, Novotna M, Paz Soldan MM, Luckey DH, Marietta EV, Jeraldo PR, Chen X, et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep. 2016;6:28484.","journal-title":"Sci Rep"},{"key":"3768_CR13","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1016\/j.cell.2022.08.021","volume":"185","author":"Consortium i","year":"2022","unstructured":"Consortium i. Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course. Cell. 2022;185:3467\u2013e34863416.","journal-title":"Cell"},{"key":"3768_CR14","doi-asserted-by":"publisher","first-page":"e2419689122","DOI":"10.1073\/pnas.2419689122","volume":"122","author":"H Yoon","year":"2025","unstructured":"Yoon H, Gerdes LA, Beigel F, Sun Y, Kovilein J, Wang J, Kuhlmann T, Flierl-Hecht A, Haller D, Hohlfeld R, et al. Multiple sclerosis and gut microbiota: Lachnospiraceae from the ileum of MS twins trigger MS-like disease in germfree transgenic mice-An unbiased functional study. Proc Natl Acad Sci U S A. 2025;122:e2419689122.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3768_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s40168-021-01101-1","volume":"9","author":"DV Guzior","year":"2021","unstructured":"Guzior DV, Quinn RA. Review: microbial transformations of human bile acids. Microbiome. 2021;9:140.","journal-title":"Microbiome"},{"key":"3768_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","volume":"9","author":"JS Fleishman","year":"2024","unstructured":"Fleishman JS, Kumar S. Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther. 2024;9:97.","journal-title":"Signal Transduct Target Ther"},{"key":"3768_CR17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41575-024-00914-3","volume":"21","author":"I Mohanty","year":"2024","unstructured":"Mohanty I, Allaband C, Mannochio-Russo H, El Abiead Y, Hagey LR, Knight R, Dorrestein PC. The changing metabolic landscape of bile acids - keys to metabolism and immune regulation. Nat Rev Gastroenterol Hepatol. 2024;21:493\u2013516.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3768_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41586-019-1785-z","volume":"576","author":"S Hang","year":"2019","unstructured":"Hang S, Paik D, Yao L, Kim E, Trinath J, Lu J, Ha S, Nelson BN, Kelly SP, Wu L, et al. Bile acid metabolites control T(H)17 and T(reg) cell differentiation. Nature. 2019;576:143\u20138.","journal-title":"Nature"},{"key":"3768_CR19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41586-020-2193-0","volume":"581","author":"C Campbell","year":"2020","unstructured":"Campbell C, McKenney PT, Konstantinovsky D, Isaeva OI, Schizas M, Verter J, Mai C, Jin WB, Guo CJ, Violante S, et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature. 2020;581:475\u20139.","journal-title":"Nature"},{"key":"3768_CR20","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1172\/JCI129401","volume":"130","author":"P Bhargava","year":"2020","unstructured":"Bhargava P, Smith MD, Mische L, Harrington E, Fitzgerald KC, Martin K, Kim S, Reyes AA, Gonzalez-Cardona J, Volsko C, et al. Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation. J Clin Invest. 2020;130:3467\u201382.","journal-title":"J Clin Invest"},{"key":"3768_CR21","doi-asserted-by":"publisher","first-page":"100522","DOI":"10.1016\/j.medj.2024.09.011","volume":"6","author":"DC Ladakis","year":"2025","unstructured":"Ladakis DC, Harrison KL, Smith MD, Solem K, Gadani S, Jank L, Hwang S, Farhadi F, Dewey BE, Fitzgerald KC, et al. Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease. Med. 2025;6:100522.","journal-title":"Med"},{"key":"3768_CR22","doi-asserted-by":"publisher","first-page":"102028","DOI":"10.1016\/j.xcrm.2025.102028","volume":"6","author":"M Antonini Cencicchio","year":"2025","unstructured":"Antonini Cencicchio M, Montini F, Palmieri V, Massimino L, Lo Conte M, Finardi A, Mandelli A, Asnicar F, Pavlovic R, Drago D, et al. Microbiota-produced immune regulatory bile acid metabolites control central nervous system autoimmunity. Cell Rep Med. 2025;6:102028.","journal-title":"Cell Rep Med"},{"key":"3768_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jneuroim.2011.11.003","volume":"242","author":"D Baker","year":"2012","unstructured":"Baker D, Amor S. Publication guidelines for refereeing and reporting on animal use in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2012;242:78\u201383.","journal-title":"J Neuroimmunol"},{"key":"3768_CR24","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","volume":"160","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, Group NCRRGW. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. 2010;160:1577\u20139.","journal-title":"Br J Pharmacol"},{"key":"3768_CR25","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1111\/bph.15193","volume":"177","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. Br J Pharmacol. 2020;177:3617\u201324.","journal-title":"Br J Pharmacol"},{"key":"3768_CR26","doi-asserted-by":"publisher","unstructured":"Pyka-Fosciak G, Fosciak M, Wojcik B, Lis GJ, Litwin JA. Histopatological parameters of the spinal cord in different phases of experimental autoimmune encephalomyelitis. A mouse model of multiple sclerosis examined by classical stainings combined with immunohistochemistry. J Physiol Pharmacol. 2023;74(4). https:\/\/doi.org\/10.26402\/jpp.2023.4.09. Epub 2023 Oct 16. PMID: 37865962.","DOI":"10.26402\/jpp.2023.4.09"},{"key":"3768_CR27","doi-asserted-by":"publisher","first-page":"7602","DOI":"10.4049\/jimmunol.0901881","volume":"183","author":"JM Fletcher","year":"2009","unstructured":"Fletcher JM, Lonergan R, Costelloe L, Kinsella K, Moran B, O\u2019Farrelly C, Tubridy N, Mills KH. CD39\u2009+\u2009Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol. 2009;183:7602\u201310.","journal-title":"J Immunol"},{"key":"3768_CR28","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1084\/jem.20062512","volume":"204","author":"S Deaglio","year":"2007","unstructured":"Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204:1257\u201365.","journal-title":"J Exp Med"},{"key":"3768_CR29","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1182\/blood-2006-12-064527","volume":"110","author":"G Borsellino","year":"2007","unstructured":"Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Hopner S, Centonze D, Bernardi G, Dell\u2019Acqua ML, et al. Expression of ectonucleotidase CD39 by Foxp3\u2009+\u2009Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110:1225\u201332.","journal-title":"Blood"},{"key":"3768_CR30","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1084\/jem.20060210","volume":"203","author":"K Koguchi","year":"2006","unstructured":"Koguchi K, Anderson DE, Yang L, O\u2019Connor KC, Kuchroo VK, Hafler DA. Dysregulated T cell expression of TIM3 in multiple sclerosis. J Exp Med. 2006;203:1413\u20138.","journal-title":"J Exp Med"},{"key":"3768_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jneuroim.2018.08.004","volume":"323","author":"A Mohammadzadeh","year":"2018","unstructured":"Mohammadzadeh A, Rad IA, Ahmadi-Salmasi B. CTLA-4, PD-1 and TIM-3 expression predominantly downregulated in MS patients. J Neuroimmunol. 2018;323:105\u20138.","journal-title":"J Neuroimmunol"},{"key":"3768_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1084\/jem.20022119","volume":"198","author":"AD Salama","year":"2003","unstructured":"Salama AD, Chitnis T, Imitola J, Ansari MJ, Akiba H, Tushima F, Azuma M, Yagita H, Sayegh MH, Khoury SJ. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med. 2003;198:71\u20138.","journal-title":"J Exp Med"},{"key":"3768_CR33","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1084\/jem.184.2.783","volume":"184","author":"NJ Karandikar","year":"1996","unstructured":"Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA. CTLA-4: a negative regulator of autoimmune disease. J Exp Med. 1996;184:783\u20138.","journal-title":"J Exp Med"},{"key":"3768_CR34","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.4049\/jimmunol.157.4.1333","volume":"157","author":"PJ Perrin","year":"1996","unstructured":"Perrin PJ, Maldonado JH, Davis TA, June CH, Racke MK. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol. 1996;157:1333\u20136.","journal-title":"J Immunol"},{"key":"3768_CR35","doi-asserted-by":"publisher","first-page":"770402","DOI":"10.3389\/fimmu.2021.770402","volume":"12","author":"L Tang","year":"2021","unstructured":"Tang L, Li G, Zheng Y, Hou C, Gao Y, Hao Y, Gao Z, Mo R, Li Y, Shen B, et al. Tim-3 Relieves Experimental Autoimmune Encephalomyelitis by Suppressing MHC-II. Front Immunol. 2021;12:770402.","journal-title":"Front Immunol"},{"key":"3768_CR36","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.4155\/fmc.15.54","volume":"7","author":"V Sepe","year":"2015","unstructured":"Sepe V, Distrutti E, Limongelli V, Fiorucci S, Zampella A. Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application. Future Med Chem. 2015;7:1109\u201335.","journal-title":"Future Med Chem"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-026-03768-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-026-03768-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-026-03768-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:40:52Z","timestamp":1776670852000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12974-026-03768-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3768"],"URL":"https:\/\/doi.org\/10.1186\/s12974-026-03768-5","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}